DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,401 filers reported holding DANAHER CORPORATION in Q2 2019. The put-call ratio across all filers is 0.58 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,533,031 | -16.5% | 6,139 | -22.6% | 0.16% | -23.3% |
Q4 2023 | $1,835,124 | +1.3% | 7,933 | +8.6% | 0.21% | -11.4% |
Q3 2023 | $1,811,829 | +2.6% | 7,303 | -0.7% | 0.24% | +4.9% |
Q2 2023 | $1,765,695 | -1.6% | 7,357 | +3.3% | 0.23% | -7.4% |
Q1 2023 | $1,795,294 | -4.5% | 7,123 | +0.6% | 0.24% | -9.6% |
Q4 2022 | $1,879,451 | -1.5% | 7,081 | -4.1% | 0.27% | -8.8% |
Q3 2022 | $1,907,740 | +2.9% | 7,386 | +1.0% | 0.30% | +10.0% |
Q2 2022 | $1,853,239 | -15.9% | 7,310 | -2.7% | 0.27% | -3.2% |
Q1 2022 | $2,204,675 | -11.0% | 7,516 | -0.2% | 0.28% | -9.7% |
Q4 2021 | $2,478,109 | +6.8% | 7,532 | -1.2% | 0.31% | -4.6% |
Q3 2021 | $2,319,837 | +8.0% | 7,620 | -4.8% | 0.32% | +8.8% |
Q2 2021 | $2,148,492 | +19.8% | 8,006 | +0.5% | 0.30% | +8.8% |
Q1 2021 | $1,793,212 | +21.8% | 7,967 | +20.3% | 0.27% | +3.0% |
Q4 2020 | $1,471,678 | +6.1% | 6,625 | +2.9% | 0.26% | -6.0% |
Q3 2020 | $1,386,941 | +22.3% | 6,441 | +0.4% | 0.28% | +11.0% |
Q2 2020 | $1,134,011 | +24.7% | 6,413 | -2.4% | 0.25% | +8.1% |
Q1 2020 | $909,077 | -11.7% | 6,568 | -2.1% | 0.24% | +6.8% |
Q4 2019 | $1,029,544 | +4.5% | 6,708 | -1.7% | 0.22% | -3.1% |
Q3 2019 | $985,446 | -2.4% | 6,823 | -3.5% | 0.23% | -5.8% |
Q2 2019 | $1,010,159 | +9.7% | 7,068 | +1.4% | 0.24% | +4.8% |
Q1 2019 | $920,575 | +29.7% | 6,973 | +1.3% | 0.23% | +13.9% |
Q4 2018 | $709,775 | -3.7% | 6,883 | +1.5% | 0.20% | +19.5% |
Q3 2018 | $737,041 | +9.7% | 6,783 | -0.4% | 0.17% | +1.8% |
Q2 2018 | $671,813 | +3.4% | 6,808 | +2.6% | 0.17% | -2.4% |
Q1 2018 | $649,437 | +6.4% | 6,633 | +0.9% | 0.17% | +4.9% |
Q4 2017 | $610,106 | +13.4% | 6,573 | +4.8% | 0.16% | +2.5% |
Q3 2017 | $537,841 | +3.9% | 6,270 | +2.2% | 0.16% | -8.1% |
Q2 2017 | $517,733 | -1.3% | 6,135 | 0.0% | 0.17% | -4.4% |
Q1 2017 | $524,727 | +4.5% | 6,135 | -4.9% | 0.18% | -4.3% |
Q4 2016 | $501,990 | -1.5% | 6,449 | -0.8% | 0.19% | -5.1% |
Q3 2016 | $509,457 | -22.6% | 6,499 | -0.2% | 0.20% | -23.8% |
Q2 2016 | $657,914 | +5.4% | 6,514 | -1.0% | 0.26% | +2.0% |
Q1 2016 | $624,084 | – | 6,579 | – | 0.26% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |